Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer

Fig. 5

Stemness analysis of PN-transfected cells compared with mock-transfected cells without or with anti-PN peptide treatment. Cells were stained with anti-CD24-FITC and anti-CD44-APC antibodies and cell with CD24−/CD44+ was marked as cancer stem cell. a-b Representative of cytogram from flow cytometer analysis. c-d Bar graph of percentage of CD24−/CD44+ cell in each condition, error bar determined SEM and n.s. = not significant

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us